Sugi Predict

Sugi Predict / Compounds / SCHEMBL1202245

SCHEMBL1202245

SCHEMBL1202245

O=C1CCC(=O)N1C(=O)OCC1c2ccccc2-c2ccccc21

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.48
▸ FABP5 Q01469 3/20 0.47
▸ FABP7 O15540 2/20 0.47
▸ EPHX2 P34913 1/20 0.45
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ CASP1 P29466 1/20 0.39
▸ MDM4 O15151 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ CASP3 P42574 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ F10 P00742 1/20 0.38
▸ DPP8 Q6V1X1 1/20 0.38
▸ DPP9 Q86TI2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30253490 1.00 KMT2A (0.48) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL29617524 1.00 KMT2A (0.48) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL7406399 0.87 CA1 (0.40) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL29178041 0.86 CA1 (0.39) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL28457176 0.85 KMT2A (0.39) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL9009565 0.83 KMT2A (0.44) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL21838309 0.83 KMT2A (0.44) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL3590981 0.83 KMT2A (0.44) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL141134 0.81 KMT2A (0.45) KMT2AFABP5FABP7EPHX2CA1
SCHEMBL22951116 0.81 KMT2A (0.45) KMT2AFABP5FABP7EPHX2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122036924-A Synthetic method of bionic collagen hexapeptide 成都欣肽生物科技有限公司 2026-05-15 — — CN claimed
CN-115716794-A Synthesis process of 9 fluorenylmethoxycarbonyl succinimide 孝义市金精化工有限公司 2023-02-28 — — CN claimed
CN-218359274-U 9-fluorenylmethoxycarbonyl succinimide's synthesizer 孝义市金精化工有限公司 2023-01-24 — — CN claimed
CN-113292456-B Preparation method of N-fluorenylmethoxycarbonyl-L-aspartic acid-4-tert-butyl ester 常州吉恩药业有限公司 2022-04-29 — — CN claimed
CN-113292456-A Preparation method of N-fluorenylmethoxycarbonyl-L-aspartic acid-4-tert-butyl ester 常州吉恩药业有限公司 2021-08-24 — — CN claimed
US-10294199-B2 Propyl cationic peptide lipids, synthesis method thereof, and application thereof DALIAN NATIONALITIES UNIVERSITY (CN) 2019-05-21 — — US claimed
CN-108931148-A A kind of pipe heat exchanger using bismuth doping effectively insulating piece 冯创英 2018-12-04 — — CN claimed
CN-108707127-A A kind of preparation method of 5 hydroxymethyl furfural decarbonylation catalyst 张玲 2018-10-26 — — CN claimed
US-20170355667-A1 PROPYL CATIONIC PEPTIDE LIPIDS, SYNTHESIS METHOD THEREOF, AND APPLICATION THEREOF DALIAN NATIONALITIES UNIVERSITY (CN) 2017-12-14 — — US claimed
CN-122102977-A Preparation method of high-purity Fmoc-S-trityl-L-penicillamine — 2026-05-29 — — CN disclosed
CN-122036924-A Synthetic method of bionic collagen hexapeptide 成都欣肽生物科技有限公司 2026-05-15 — — CN disclosed
US-20260132164-A1 PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC (US) 2026-05-14 — — US disclosed
US-20260070945-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY 2026-03-12 — — US disclosed
US-20260022142-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL MYERS SQUIBB CO (US) 2026-01-22 — — US disclosed
WO-1997035182-A1 PEPTIDYL FLUORESCENT CHEMOSENSOR FOR DIVALENT ZINC CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 1997-09-25 — — WO disclosed
EP-0592791-A2 Tricyclic compounds and peptide derivatives thereof F. HOFFMANN-LA ROCHE AG (CH) 1994-04-20 — — EP disclosed
EP-0531443-A4 METHODS FOR TREATING INFLAMMATION AND COMPOUNDS AND COMPOSITIONS SUITABLE FOR USE THEREIN — 1993-04-21 — — EP disclosed
EP-0531443-A1 METHODS FOR TREATING INFLAMMATION AND COMPOUNDS AND COMPOSITIONS SUITABLE FOR USE THEREIN NOVA PHARMACEUTICAL CORPORATION (US) 1993-03-17 — — EP disclosed
US-5079260-A Side effect reduction; fluorene derivatives NOVA PHARMACEUTICAL CORPORATION (US) 1992-01-07 — — US disclosed
WO-1991018596-A1 METHODS FOR TREATING INFLAMMATION AND COMPOUNDS AND COMPOSITIONS SUITABLE FOR USE THEREIN WEITZBERG MOSHE (US) 1991-12-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355667-A1 PROPYL CATIONIC PEPTIDE LIPIDS, SYNTHESIS METHOD THEREOF, AND APPLICATION THEREOF PCNP, PLIN1, PLIN3 KMT2A 3470/4885FABP5 797/4885FABP7 331/4885
US-20260022142-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 KMT2A 1052/4885FABP5 2537/4885FABP7 2103/4885
US-20260070945-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1, PDCD1LG2 KMT2A 1528/4885FABP5 1949/4885FABP7 2027/4885
US-10294199-B2 Propyl cationic peptide lipids, synthesis method thereof, and application thereof PCNP, PLIN1, PLIN3 KMT2A 3470/4885FABP5 797/4885FABP7 331/4885
US-20260132164-A1 PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF TOP1, NCL, NOLC1 KMT2A 4182/4885FABP5 4520/4885FABP7 4374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.